All lobbying filings

ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $430,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 4993
Joe Fiandra Access to Home Infusion Act of 2025
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 3

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.